We report herein the first synthesis of biologically active natural bromophenols, namely 1-(2,3,6-tribromo-4,5-dihydroxybenzyl)pyrrolidin-2-one (2), 2RS-1-(2,3-dibromo-4,5-dihydroxybenzyl)-5-oxopyrrolidine-2-carboxylic acid (3), and 2RS-methyl 1-(2,3-dibromo-4,5-dihydroxybenzyl)-5-oxopyrrolidine-2-carboxylate (4), along with their different derivatives (6 and 8-18). Among the synthesized compounds, 3, 4, and their derivatives (8 and 9) are yielded in racemic form. Radical scavenging assays of the synthesized molecules were investigated using various bioanalytical antioxidant methods including 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS antioxidant compounds of α -tocopherol, trolox, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT).
Abstract:
We report herein the first synthesis of biologically active natural bromophenols, namely 1-(2,3,6-tribromo-4,5-dihydroxybenzyl)pyrrolidin-2-one (2), 2RS-1-(2,3-dibromo-4,5-dihydroxybenzyl)-5-oxopyrrolidine-2-carboxylic acid (3) , and 2RS-methyl 1-(2,3-dibromo-4,5-dihydroxybenzyl)-5-oxopyrrolidine-2-carboxylate (4), along with their different derivatives (6 and 8-18). Among the synthesized compounds, 3, 4, and their derivatives (8 and 9) are yielded in racemic form. Radical scavenging assays of the synthesized molecules were investigated using various bioanalytical antioxidant methods including 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS •+ ) and 2,2-diphenyl-1- 
picrylhydrazyl (DPPH •
)
Introduction
Natural or synthetic bromophenols exhibit important biological activities such as feeding deterrent 1 antioxidant,
antimicrobial, 5, 6 and inhibition effects on carbonic anhydrase enzyme. 7−12 Naturally occurring bromophenols are abundantly found in marine life and frequently isolated from red algae of the family Rhodomelaceae.
13−15
Natural bromophenols 1-4 were isolated from marine red algae 2,16−19 and exhibited antioxidant activities ( Figure) . 2,16−19 It was also reported that compound 2 inhibition had ability on protein tyrosine phosphatase 1B. 17, 18 The synthesis of compound 1 and its derivatives like racemate as well as their antioxidant activities were firstly reported by our group.
20
Reactive oxygen species (ROS), which contain free radicals such as hydroxyl radicals (OH • ), superoxide anion radicals (O
•−
2 ), or nonfree radical species such as singlet oxygen ( 1 O 2 ) and hydrogen peroxide (H 2 O 2 ), are diverse types of activated oxygen. 21−23 There is an equilibrium between the formation of ROS molecules and antioxidant defense systems in living organisms. 21 The oxidative stress process occurs when the generation of ROS is higher than the protective ability of the antioxidant defense systems. 24 Under pathological situations, ROS molecules are overproduced and this results in oxidative stress. Additionally, ROS are created when inner antioxidant defenses are incomplete. 25 The imbalance between the antioxidant defense systems and ROS leads to oxidative correction in the intracellular molecules or cellular membrane. 26−28 The oxidative stress has been defined as a key research concern due to its significant role in human diseases such as atherosclerosis, brain dysfunction, and cancer. 29 Antioxidant compounds are bioactive molecules generally used for the protection of cellular compounds in living metabolisms. They maintain food quality and prevent oxidative rancidity.
30−32
Antioxidant molecules eliminate free radicals and protect the human body from cancers, chronic cardiovascular diseases, and ageing by removing or neutralizing ROS.
33
The most commonly used processes to treat Alzheimer disease (AD) are centralized to impede the hydrolysis of acetylcholine (ACh) in cholinergic neurons and hinder synaptic depression. This process is called the cholinergic hypothesis and was recently used in the extension of drugs capable of elevating chemical balance in the slope of the concentration of ACh in patients with AD. 34 AChE performs a main role in ACh hydrolysis in the neural device. 35 The hydrolysis of ACh could be stopped by inhibiting AChE activity. Therefore, different AChE inhibitors (AChEIs) are used in AD therapy. Among them the compound tacrine was the first drug recorded by the Food and Drug Administration (FDA), followed by rivastigmine, galantamine, and donepezil. These compounds as drugs are defined for treating moderate and mild phases of AD, when the patient still enjoys autonomous cognitive acts. 36 AChEIs can be classified as weak or strong inhibitors. Strong inhibitors contain carbamates and organic phosphates, which are frequently used as pesticides and neural toxins, while weak inhibitors have been used in the treatment of Parkinson disease, AD, dementia with Lewy bodies, glaucoma, myasthenia gravis, autism, postural tachycardia syndrome, cognitive disturbances, and insomnia. 37 Cholinergic neurotransmission in the mammalian brain could stop by the hydrolysis of ACh, which is catalyzed by two cholinesterases (ChEs): AChE and BChE. BChE is also used as drug for the therapy of AD at advanced stage. Selective BChE inhibition is significantly beneficial, because it does not have classical cholinergic toxicity, which is a prevalent side effect of AChE inhibitors. 38 It has been recorded that some phenolic molecules had a large potential of biological activity including AChE and BChE inhibition effects and antioxidant properties.
39
To the best of our knowledge, the synthesis of natural bromophenols 2-4 was not reported in the literature previously. The synthesis of them will make a significant contribution to the field because they are natural products and might exhibit potential biological activity such as antioxidant. Therefore, in this study, the synthesis of them and their derivatives was realized and their antioxidant and anticholinergic activities were investigated.
Results and discussion

Chemistry
Biologically active natural bromophenols 2-4 are N-benzylpyrrolidin-2-one derivatives (Figure) . In addition to OH groups in positions 3 and 4 in their benzene rings, three Br in positions 2, 3, and 6 in 2 and two Br in positions 2 and 3 in the others (3 and 4) are found. Additionally, COOH and COOMe groups are found in the pyrrolidone rings of 3 and 4, respectively. For the synthesis of these natural bromophenols 2-4, our method is based on the preparation of benzylic rings with OMe and Br followed by their connection to the corresponding pyrrolidinone rings. Hydroxy (OH) groups are converted to OMe moieties because of the better identification and solubility of the products. It was reported that N-benzyl-2-pyrrolidone could be synthesized from the reaction of benzyl bromide and 2-pyrrolidinone in the presence of KOH and TBAB (tetrabutylammonium bromide). For the synthesis of natural bromophenols 3 and 4, tribromide 7 was obtained from the corresponding reactions using vanillin as starting material. 20, 41, 42 The reaction of synthesized methyl 5-oxopyrrolidine-2-carboxylate in the basic condition only gave 8, precursor compounds of natural products 3 and 4. To use compound 9 in the demethylation reaction of natural products 3 and 4, compound 8 was also converted into compound 9. Reactions of each compound 6, 8, and 9 with BBr 3 in CH 2 Cl 2 gave the natural bromophenols 2, 3, and 4, respectively.
Derivatives with different numbers of Br, without Br and OMe of biologically active natural bromophenol 2 will be important because they might show biological activities. For the synthesis of derivatives 10-14, corresponding bromides 5 and 7 were synthesized by known methods. 20,41−44 The derivatives 10-14 were obtained from the reactions of these bromides and 2-pyrrolidinone with NaH in THF (Scheme 2). Similar to the synthesis of bromophenol 2 from the reaction of 6 with BBr 3 , phenol derivatives 15-18 were obtained by demethylations of derivatives 10-13 (Scheme 2). The corresponding phenol derivative could not be obtained from the demethylation reaction of 14 with BBr 3 .
Scheme 2. Some derivatives of natural bromphenol 2 and their synthesis.
Biological activities
Antioxidant results
Antioxidant activity, which reflected the ability of pure compounds, can inhibit the oxidation process in living systems. In this study, several different antioxidant assays based on different reaction mechanisms were used to detect the potent antioxidant activity of novel 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenols.
The following results should be noted regarding the inhibition of CA, AChE, and BChE enzymes and antioxidant activities of novel bromophenols:
i. The first antioxidant assay performed is based on the Fe 3+ reduction method. Generally, reducing
properties of a compound depend on its reducing power, which have been shown to exert antioxidant activity and radical scavenging ability by donating a hydrogen atom. 45 The Fe 3+ (CN − ) 6 reduction procedure detects the antioxidant effect of any molecule as measuring reducing ability in the reaction. Some 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenols including natural products of 2-4 and some of the other compounds (15-18) had potent reducing activity using Fe 3+ (CN − ) 6 when compared with the standards (α -tocopherol, trolox, BHT, and BHA). It can be seen in Table 1 . The CUPRAC assay is a simple, rapid, cost-effective, selective, steady, and versatile antioxidant assay useful for a wide variety of polyphenols, as well as for thiols and synthetic antioxidants. 46 The ortho-substitution of HO − groups with electron-donating groups like methoxy groups (-OCH 3 ) can also increase antioxidant activity. For example the -CH=CH-COOH groups in cinnamic acid can produce greater H-donating ability and subsequent antioxidant activity than the -COOH groups in benzoic acids through stabilizing the radical by resonance of -C=C-.
iii. The FRAP method measures the capability of antioxidants to reduce the ferric 2,4,6-tripyridyl-s-triazine iv. The DPPH radical is one of the few stable organic nitrogen radicals and is deep purple. This method is based on the measurement of the neutralizing capability of antioxidants toward DPPH radicals. 52 Table 2 shows half maximal radical scavenging concentrations (IC 50 ) of novel 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenols and the reference radical scavenger types including BHA, BHT, trolox, and 0.9102) ( Table 2 ). Chelation of ferrous ions (Fe 2+ ) may protect the cells against molecular oxidative damage by inhibiting production of ROS.
Results of anticholinesterase activity
I. AD is a life-threatening illness that accounts for 60%-80% of cases of dementia and that is the sixth leading cause of death in the world. 55 Generally, the final assessment comes at a late step of the disease because clinical signs are difficult to know and AD-relevant biomarkers are not largely accepted. Therapeutic drugs used to treat AD are ChEIs, which are considered to raise availability of ACh, thereby improving cognitive processes, i.e. attention and memory. 56 Indeed, three separate parts in the active site comprise selectivity of BChE inhibitors: the first part is acyl binding pocket, second part is determined near the lip of active site gorge, and the third part is recorded as the choline binding site. Molecules, which can affect these BChE parts via metal interactions or hydrophobic, hydrogen bonding, and salt bridges can create their inhibitory action. 57 In this work, AChE was also extremely inhibited by novel antioxidant bromophenols at the low nanomolar concentrations with K i values in the range of 2.60 ± 0.75-16.36 ± 2.67 nM (Table   3) . These results clearly determined that the new synthesized bromophenols had effective AChE inhibition properties. However, the most powerful AChE inhibition was recorded by novel bromophenol 9 with a K i value of 2.60 ± 0.75 nM. Moreover, all the remaining newly synthesized bromophenols reported here had highly efficient inhibition constants against AChE. Additionally, tacrine (1, 2, 3, 4-tetrahydroacridin-9-amine), which was the first centrally acting cholinesterase inhibitor recorded for the therapy of AD, showed a K i value of 86.37 ± 14.10 nM against AChE.
II. Finally, new antioxidant bromophenols inhibited BChE with K i values in the range of 13.10 ± 3.33-54.47 ± 13.53 nM ( Table 3) . The K i values of the new antioxidant bromophenols for BChE and AChE were obtained from Lineweaver-Burk plots. On the other hand, tacrine, which was the first cholinesterase inhibitor to be discovered for the management of AD symptoms in 1993, had a K i value of 100.40 ± 15.62 nM. Furthermore, it was considered that donepezil hydrochloride, which is used for the therapy of mildto-moderate AD and other diverse memory impairments, was shown to lower AChE inhibition activity (IC 50 : 55.0 nM). 58 As seen in 
Conclusion
Biologically active natural bromophenols 2-4, tetrabromide 5, 41, 42 and tribromide 7 20, 41, 42 were synthesized using the procedures described in the literature. Demethylation of compound 6, obtained from the reaction of tetrabromide 5, yielded natural bromophenol 2. In a similar manner, other natural bromophenols 3 and 4 were also synthesized from 8 and 9. Besides the first synthesis of bromophenols 2-4, the derivatives 10-18 of 2 were synthesized as well. Among these compounds, 3, 4, 8, and 9 are racemic compounds. Additionally, the synthesized compounds were evaluated for antioxidant and anticholinergic activities.
Experimental
General
Solvents were purified and dried by known methods. 
1-(2,3-Dibromo-4,5-dihydroxybenzyl)pyrrolidin-2-one (2): standard procedure for the demethylation reaction with BBr 3 (3, 4, 15-18)
A solution of BBr 3 (0.53 g, 2.12 mmol) in CH 2 Cl 2 (7 mL) was added dropwise into cold (0 • C) solution of compound 6 (0.50 g, 1.1 mmol) stirred in CH 2 Cl 2 (15 mL) under N 2 (g) over 7 min, and the mixture was stirred at the same temperature for 20 min. After the cold bath was removed, the mixture was stirred at RT and under N 2 for 16 h. Then methanol (3 mL) was slowly added to the mixture over 15 min at 0 • C. Next, the solvent was evaporated and then water (25 mL) was added. After the mixture was extracted with EtOAc (2 × 30 mL), the combined organic phases were dried over Na 2 SO 4 and the solvent was evaporated. Natural product 2 (310 mg, 65%) was obtained as white amorphous solid. 
2,3-Dibromo-1-(bromomethyl)-4,5-dimethoxybenzene (7)
To a stirred cold (0 • C) mixture of 2,3-dibromo-4,5-dimethoxybenzaldehyde (1.0 g, 3.09 mmol), methanol (10 mL), and diethyl ether (5 mL) NaBH 4 (114 mg, 3.09 mmol) was carefully added in portions over 15 min. After the mixture was stirred at the same temperature for half an hour, the cold bath (ice-water) was removed and the reaction progress was monitored by thin-layer chromatography while the mixture was stirred at RT for 4 h. After the solvent was evaporated, water (20 mL) was added and the resulting mixture was extracted with EtOAc (2 × 15 mL), the combined organic phases were dried over Na 2 SO 4 , and the solvent was evaporated.
To cold (0 • C) solution of the residue including reduction product in CH 2 Cl 2 (20 mL) was added Et 3 N (0.374 g, 3.70 mmol). After the mixture was stirred at the same temperature for 0.5 h, PBr 3 (1.00 g, 3.70 mmol) was added dropwise and the mixture was additionally stirred for 24 h. As stated above, the remainder of this substitution reaction was realized according to that of the reduction reaction of the aldehyde. Known 
(2RS)-1-(2,3-dibromo-4,5-dimethoxybenzyl)-5-oxopyrrolidine-2-carboxylic acid (8)
This reaction was realized according to the standard procedure described in the synthesis of 6. 
(2RS)-Methyl 1-(2,3-dibromo-4,5-dimethoxybenzyl)-5-oxopyrrolidine-2-carboxylate (9)
A solution of the compound 8 (100 mg, 0.229 mmol) and SOCl 2 (544 mg, 4.58 mmol) in CH 2 Cl 2 (8 mL) was stirred at RT for 12 h. After the solvent was removed under vacuum and methanol was added, the formed solution was stirred for 1 h. 
(2RS)-1-(2,3-dibromo-4,5-dihydroxybenzyl)-5-oxopyrrolidine-2-carboxylic acid (3)
This reaction was realized according to the standard procedure described in the synthesis of 2. 
(2RS)-Methyl 1-(2,3-dibromo-4,5-dihydroxybenzyl)-5-oxopyrrolidine-2-carboxylate (4)
1-(2,3-Dibromo-4,5-dimethoxybenzyl)pyrrolidin-2-one (10)
1-(3-Bromo-4,5-dimethoxybenzyl)pyrrolidin-2-one (11)
This reaction was realized according to the standard procedure described in the synthesis of 6. 314.0374.
1-(2-Bromo-4,5-dimethoxybenzyl)pyrrolidin-2-one (12)
This reaction was realized according to the standard procedure described in the synthesis of 6. 2-Pyrrolidinone (220 mg, 2.58 mmol), THF (20 mL), 1-bromo-2-(bromomethyl)-4,5-dimethoxybenzene (0. 
1-(4-Methoxybenzyl)pyrrolidin-2-one (13)
1-(3-Bromo-4-methoxybenzyl)pyrrolidin-2-one (14)
To a solution of compound 13 (200 mg, 0.97 mmol) in CH 2 Cl 2 (15 mL), molecular bromine (622 mg, 3.90 mmol) was added. After the solution was stirred in the dark at RT for 16 h, the solvent was removed under vacuum and compound 14 (275 mg, 100%) was obtained alone. 
1-(2-Bromo-4,5-dihydroxybenzyl)pyrrolidin-2-one (17)
1-(4-Hydroxybenzyl)pyrrolidin-2-one (18)
The synthesis of compound 18 was realized according to the standard procedure described in the synthesis of 2. 
DPPH • scavenging activity
The DPPH • scavenging activity of the novel 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenols was designated as previously explained. 65 Briefly, fresh solution of DPPH radicals (0.1 mM) was prepared in ethanol. Then 1.5 mL of each novel 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenol in ethanol was added to an aliquot of this solution (0.5 mL, 10-30 µ g/mL). These mixtures were mixed vigorously and incubated in the dark for 30 min. Finally the absorbance value was recorded at 517 nm in a spectrophotometer. 
ABTS •+ scavenging activity
The ABTS radical scavenging capacity of the novel 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenols was characterized using the spectroscopic procedure explained by Re et al. 67 The 
AChE/BChE activity determination and inhibition studies
The inhibitory efficacy of the novel 1-(4,5-dihydroxybenzyl)pyrrolidin-2-one derivative bromophenols on BChE/AChE activities was obtained conforming to the spectrophotometric procedure of Ellman et al. 69 as described previously. 70 Butrylcholine iodide (BChI) and also acetylthiocholine iodide (AChI) compounds were used as 
